Jump to content

Main menu Navigation ●Main page ●Contents ●Current events ●Random article ●About Wikipedia ●Contact us ●Donate Contribute ●Help ●Learn to edit ●Community portal ●Recent changes ●Upload file

●Create account ●Log in ●Create account ● Log in Pages for logged out editors learn more ●Contributions ●Talk

(Top) 1 References

Picoplatin

●تۆرکجه ●فارسی ●Bahasa Indonesia ●日本語 ●Русский ●Српски / srpski ●Srpskohrvatski / српскохрватски Edit links ●Article ●Talk ●Read ●Edit ●View history Tools Actions ●Read ●Edit ●View history General ●What links here ●Related changes ●Upload file ●Special pages ●Permanent link ●Page information ●Cite this page ●Get shortened URL ●Download QR code ●Wikidata item Print/export ●Download as PDF ●Printable version Appearance From Wikipedia, the free encyclopedia

Picoplatin
Names

IUPAC name azane; 2-methylpyridine; platinum(2+); dichloride
Identifiers
CAS Number	181630-15-9^Y
3D model (JSmol)	ionic form: Interactive image coordination form: Interactive image
ChemSpider	154428^N
ECHA InfoCard	100.205.233
PubChem CID	177358
UNII	B5TAN0L720^Y
CompTox Dashboard (EPA)	DTXSID10939458
InChI InChI=1S/C6H7N.2ClH.H3N.Pt/c1-6-4-2-3-5-7-6;;;;/h2-5H,1H3;21H;1H3;/q;;;;+2/p-2^N Key: IIMIOEBMYPRQGU-UHFFFAOYSA-L^N InChI=1/C6H7N.2ClH.H3N.Pt/c1-6-4-2-3-5-7-6;;;;/h2-5H,1H3;21H;1H3;/q;;;;+2/p-2 Key: IIMIOEBMYPRQGU-NUQVWONBAG
SMILES ionic form: Cc1ccccn1.N.[Cl-].[Cl-].[Pt+2] coordination form: Cl[Pt-2](Cl)([NH3+])[n+]1ccccc1C
Properties
Chemical formula	C₆H₁₀Cl₂N₂Pt
Molar mass	376.14 g·mol⁻¹
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa). N verify (what is ^YN ?) Infobox references

Picoplatin is a platinum-based antineoplastic agent in clinical development by Poniard Pharmaceuticals (previously NeoRx) for the treatment of patients with solid tumors.^[1]

In Phase I and Phase II clinical trials, picoplatin demonstrated activity in a variety of solid tumors, including lung, ovarian, colorectal and hormone-refractory prostate cancer.^[2] However, in Phase III trials, picoplatin failed to hit its primary endpoint for advanced small cell lung cancer.^[3] Hopes are now pinned on its use for metastatic colorectal cancer.^[4]